Blue test tubes arranged in a line, disappearing into the background

Drug news

Alogliptin (Takeda) filed at EMA for Type 2 Diabetes

Read time: 1 mins

Last updated:23rd May 2012

Published:23rd May 2012

Source: Pharmawand

The European Medicines Agency has accepted for review alogliptin,a selective dipeptidyl peptidase IV (DPP-4) inhibitor from Takeda for Type 2 Diabetes. The filing is based on trials involving more than 11,000 patients and several ongoing studies, including the EXAMINE trial which is evaluating cardiovascular endpoints following treatment with alogliptin. The FDA has isssued a Complete Response Letter in respect to the American application.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Results from the Phase III ARANOTE trial have shown that darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with metastatic hormone-sensitive prostate cancer (mHSPC)

4 mins

Drug news

Ten-year data for Keytruda (pembrolizumab) demonstrates sustained overall survival benefit versus ipilimumab in advanced melanoma

Merck ( known as MSD outside of the United States and Canada ) announced long-term overall survival (OS) data from the pivotal Phase III KEYNOTE-006 trial, evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma

2 min

Drug news

FDA approval of dupixent (dupilumab) to treat rhinosinusitis with nasal polyps

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

1 min

See all news